Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04738799
Other study ID # 20-03021613
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 29, 2021
Est. completion date July 3, 2023

Study information

Verified date October 2023
Source Weill Medical College of Cornell University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to explain the effect of food order/nutrient sequencing on glycemic excursions over a 2 week period, utilizing a device known as a continuous glucose monitor (CGM), for people who have been diagnosed with Type 2 Diabetes Mellitus and treated with metformin. This research study is being done because recent studies demonstrate that besides carbohydrate amount and type, the sequential order of macronutrient consumption during a meal has a significant impact on post-meal glucose levels.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date July 3, 2023
Est. primary completion date July 3, 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Metformin-treated type 2 diabetes of less than 10 years duration - Must be on a stable dose of metformin for at least 1 month - HbA1c =8.5 percent Exclusion Criteria: - Relevant food allergies - Oral steroid therapy within 90 days of enrollment - Anti-diabetic medications other than metformin - History of bariatric surgery - Pregnant women - Any participant deemed unsuitable in the investigator's opinion

Study Design


Intervention

Behavioral:
Carbohydrate-Last Meal Sequence
Carbohydrates consumed last during mealtimes for 6 days
Carbohydrate-First Meal Sequence
Carbohydrates consumed first during mealtimes for 6 days

Locations

Country Name City State
United States Weill Cornell Medicine New York New York

Sponsors (1)

Lead Sponsor Collaborator
Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in incremental glucose peak, under controlled conditions Day 6, Day 12
Primary Change in mean amplitude of glycemic excursion, under controlled conditions Day 6, Day 12
Primary Change in time in range, under controlled conditions Time during which participant maintained a blood glucose level between 70-180mg/dL over 8 hour observation period Day 6, Day 12
Secondary Change in incremental glucose peak, under free-living conditions Day 1 through 5, Day 7 through 11
Secondary Change in mean amplitude of glycemic excursion, under free-living conditions Day 1 through 5, Day 7 through 11
Secondary Change in time in range, under free-living conditions Time during which participant maintained a blood glucose level between 70-180mg/dL Day 1 through 5, Day 7 through 11
Secondary Change in postprandial insulin concentration Postprandial concentrations of insulin measured at 30-minute intervals for 180 minutes following standardized meal administration. Day 6, Day 12
Secondary Change in postprandial c-peptide concentration Postprandial concentrations of c-peptide measured at 30-minute intervals for 180 minutes following standardized meal administration. Day 6, Day 12
Secondary Change in postprandial ghrelin concentration Postprandial concentrations of ghrelin measured at 30-minute intervals for 180 minutes following standardized meal administration. Day 6, Day 12
Secondary Change in postprandial PYY concentration Postprandial concentrations of PYY measured at 30-minute intervals for 180 minutes following standardized meal administration. Day 6, Day 12
Secondary Change in postprandial GLP-1 concentration Postprandial concentrations GLP-1 measured at 30-minute intervals for 180 minutes following standardized meal administration. Day 6, Day 12
Secondary Change in postprandial CCK concentration Postprandial concentrations of CCK measured at 30-minute intervals for 180 minutes following standardized meal administration. Day 6, Day 12
Secondary Change in satiety, as measured by Visual Analog Scale (VAS) Scores are measured on a 100mm VAS. The VAS ranges from 0 to 100, with 0 indicating lower satiety and higher scores indicating greater satiety. Day 6, Day 12
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A